MedTrace Logo

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

NCT04156269 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-11-12

No results posted yet for this study

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

BCMA-CS1 cCAR T cells

BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.

Sponsors & Collaborators

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Chengdu Military General Hospital

    collaborator OTHER

  • iCAR Bio Therapeutics Ltd.

    collaborator INDUSTRY

  • iCell Gene Therapeutics

    lead INDUSTRY

Principal Investigators

  • Hongyu Zhang, MD, PhD · Peking University Shenzhen Hospital

  • Fang Liu, MD, PhD · Chengdu Military General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2021-09-01
Completion
2021-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04156269 on ClinicalTrials.gov